Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors while in the central nervous method, conolidine modulates alternate molecular targets. A Science Improvements review observed that conolidine interacts Together with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid https://jimh146lhz3.wikicorrespondence.com/user